Prognostic significance of expression of eukaryotic initiation factor 4E and 4E binding protein 1 in patients with pathological stage I invasive lung adenocarcinoma

Lung Cancer

Volumn 70, Issue 3, 2010, Pages 329-334

  Seki, Nobuhiko ^a   Takasu, Tasaburo ^b   Sawada, Shigeki ^c   Nakata, Masao ^d   Nishimura, Rieko ^c   Segawa, Yoshihiko ^c   Shibakuki, Reishi ^e   Hanafusa, Toshiaki ^b   Eguchi, Kenji ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EIF4E; EIF4E binding protein 1; Lung adenocarcinoma; Prognosis; Translational control

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; AGED; DISEASE PROGRESSION; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHOSPHOPROTEINS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78049401290     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.03.006     Document Type: Article

References (43)

1. Devesa S.S., Bray F., Vizcaino A.P., Parkin D.M. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005, 117:294-299.
2. Naruke T., Tsuchiya R., Kondo H., Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001, 71:1759-1764.
3. Hershey J.W. Translational control in mammalian cells. Annu Rev Biochem 1991, 60:717-755.
4. Gallie D.R. A tale of two termini: a functional interaction between the termini of an mRNA is a prerequisite for efficient translation initiation. Gene 1998, 216:1-11.
5. Clemens M.J. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004, 23:3180-3188.
6. Raught B., Gingras A.C. eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 1999, 31:43-57.
7. Lazaris-Karatzas A., Montine K.S., Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature (Lond.) 1990, 345:544-547.
8. De Benedetti A., Rhoads R.E. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc Natl Acad Sci USA 1990, 87:8212-8216.
9. Polunovsky V.A., Rosenwald I.B., Tan A.T., et al. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 1996, 16:6573-6581.
10. Kevil C.G., De Benedetti A., Payne D.K., Coe L.L., Laroux F.S., Alexander J.S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 1996, 65:785-790.
11. Shatkin A.J. Capping of eucaryotic mRNAs. Cell 1976, 9:645-653.
12. Duncan R., Milburn S.C., Hershey J.W. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem 1987, 262:380-388.
13. Hiremath L.S., Webb N.R., Rhoads R.E. Immunological detection of the messenger RNA cap-binding protein. J Biol Chem 1985, 260:7843-7849.
14. De Benedetti A., Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23:3189-3199.
15. Li S., Takasu T., Perlman D.M., et al. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003, 278:3015-3022.
16. Ruggero D., Montanaro L., Ma L., et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004, 10:484-486.
17. Jacobson B.A., Alter M.D., Kratzke M.G., et al. Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 2006, 66:4256-4262.
18. Poulin F., Gingras A.C., Olsen H., Chevalier S., Sonenberg N. 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J Biol Chem 1998, 273:14002-14007.
19. Jiang H., Coleman J., Miskimins R., Miskimins W.K. Expression of constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int 2003, 3:2.
20. Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 2008, 86:178-183.
21. Thumma S.C., Kratzke R.A. Translational control: a target for cancer therapy. Cancer Lett 2007, 258:1-8.
22. Armengol G., Rojo F., Castellví J., et al. 4E-binding protein 1: a key molecular " funnel factor" in human cancer with clinical implications. Cancer Res 2007, 67:7551-7555.
23. Martin M.E., Perez M.I., Redondo C., Alvarez M.I., Salinas M., Fando J.L. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000, 32:633-642.
24. Salehi Z., Mashayekhi F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin Biochem 2006, 39:404-409.
25. Travis W.D. Pathology and genetics of tumours of the lung, thymus and heart (World Health Organization classification of tumours) 2004, Intl Agency for Research on Cancer. 1st ed.
26. Travis W.D., Garg K., Franklin W.A., et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 2006, 1:S13-S19.
27. Seki N., Takasu T., Mandai K., et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res 2002, 8:3046-3053.
28. Rosenwald I.B., Hutzler M.J., Wang S., Savas L., Fraire A.E. Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 2001, 92:2164-2171.
29. Kenerson H.L., Aicher L.D., True L.D., Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002, 62:5645-5650.
30. Castellvi J., Garcia A., Rojo F., et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006, 107:1801-1811.
31. Rojo F., Najera L., Lirola J., et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007, 13:81-89.
32. Gridelli C., Maione P., Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008, 13:139-147.
33. Graff J.R., Konicek B.W., Carter J.H., Marcusson E.G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008, 68:631-634.
34. Graff J.R., Konicek B.W., Vincent T.M., et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007, 117:2638-2648.
35. Chi K.N., Eisenhauer E., Fazli L., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005, 97:1287-1296.
36. Takano T., Fukui T., Ohe Y., et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008, 26:5589-5595.
37. Zhu C.Q., da Cunha Santos G., Ding K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:4268-4275.
38. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26:3351-3357.
39. Feigenblum D., Schneider R.J. Cap-binding protein (eukaryotic initiation factor 4E) and 4E-inactivating protein BP-1 independently regulate cap-dependent translation. Mol Cell Biol 1996, 16:5450-5457.
40. Dilling M.B., Germain G.S., Dudkin L., et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002, 277:13907-13917.
41. Sun S.Y., Rosenberg L.M., Wang X., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65:7052-7058.
42. Wang R., Geng J., Wang J.H., Chu X.Y., Geng H.C., Chen L.B. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. Lung Cancer 2009, March. [Epub ahead of print].
43. Khoury T., Alrawi S., Ramnath N., et al. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 2009, 10:58-66.